{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:55:16Z","timestamp":1792428916485,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T00:00:00Z","timestamp":1494460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is a rare malignant neoplasm of the olfactory mucosa. Despite surgical resection combined with radiotherapy and adjuvant chemotherapy, ENB often relapses with rapid progression. Current multimodality, nontargeted therapy for relapsed ENB is of limited clinical benefit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We queried whether comprehensive genomic profiling (CGP) of relapsed or refractory ENB can uncover genomic alterations (GA) that could identify potential targeted therapies for these patients. CGP was performed on formalin-fixed, paraffin-embedded sections from 41 consecutive clinical cases of ENBs using a hybrid-capture, adaptor ligation based next-generation sequencing assay to a mean coverage depth of 593X. The results were analyzed for base substitutions, insertions and deletions, select rearrangements, and copy number changes (amplifications and homozygous deletions).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Clinically relevant GA (CRGA) were defined as GA linked to drugs on the market or under evaluation in clinical trials. A total of 28 ENBs harbored GA, with a mean of 1.5 GA per sample. Approximately half of the ENBs (21, 51%) featured at least one CRGA, with an average of 1 CRGA per sample. The most commonly altered gene was TP53 (17%), with GA in PIK3CA, NF1, CDKN2A, and CDKN2C occurring in 7% of samples.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We report comprehensive genomic profiles for 41 ENB tumors. CGP revealed potential new therapeutic targets, including targetable GA in the mTOR, CDK and growth factor signaling pathways, highlighting the clinical value of genomic profiling in ENB.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0287","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T01:10:32Z","timestamp":1494551432000},"page":"834-842","source":"Crossref","is-referenced-by-count":58,"title":["Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options"],"prefix":"10.1093","volume":"22","author":[{"given":"Laurie M.","family":"Gay","sequence":"first","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungeun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology Albany Medical College, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Fedorchak","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madappa","family":"Kundranda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Banner MD Anderson Cancer Center, Gilbert, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazmin","family":"Odia","sequence":"additional","affiliation":[{"name":"Department of Neurology Columbia University - NY Presbyterian Medical Center, New York, New York, USA"},{"name":"Department of Neuro-Oncology Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitali","family":"Nangia","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, UC Irvine, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Battiste","sequence":"additional","affiliation":[{"name":"Department of Neurology Stephenson Cancer Center at Oklahoma University, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Colon-Otero","sequence":"additional","affiliation":[{"name":"Department of Oncology Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Powell","sequence":"additional","affiliation":[{"name":"Sanford Health, Sioux Falls, South Dakota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Elvin","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Anne","family":"Vergilio","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Suh","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj M.","family":"Ali","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Miller","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"},{"name":"Department of Pathology Albany Medical College, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,11]]},"reference":[{"key":"2021122508122609900_onco12140-bib-0001","author":"Barnes","year":"2007"},{"key":"2021122508122609900_onco12140-bib-0002","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MOO.0000000000000220","article-title":"Contemporary management of esthesioneuroblastoma","volume":"24","author":"Schwartz","year":"2016","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"2021122508122609900_onco12140-bib-0003","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/PAP.0b013e3181b544cf","article-title":"Olfactory neuroblastoma: A review and update","volume":"16","author":"Faragalla","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"2021122508122609900_onco12140-bib-0004","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2006.09.024","article-title":"Comprehensive cytogenetic characterization of an esthesioneuroblastoma","volume":"173","author":"Holland","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"2021122508122609900_onco12140-bib-0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0165-4608(01)00659-8","article-title":"Analysis of cytogenetic aberrations in esthesioneuroblastomas by comparative genomic hybridization","volume":"136","author":"Riazimand","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"2021122508122609900_onco12140-bib-0006","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/BF01411401","article-title":"Olfactory neuroblastoma: Detection of genomic imbalances by comparative genomic hybridization","volume":"139","author":"Szymas","year":"1997","journal-title":"Acta Neurochir (Wien)"},{"key":"2021122508122609900_onco12140-bib-0007","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1750-3639.2004.tb00048.x","article-title":"CGH pattern of esthesioneuroblastoma and their metastases","volume":"14","author":"Bockmuhl","year":"2004","journal-title":"Brain Pathol"},{"key":"2021122508122609900_onco12140-bib-0008","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/modpathol.2008.57","article-title":"Array comparative genomic hybridization analysis of olfactory neuroblastoma","volume":"21","author":"Guled","year":"2008","journal-title":"Mod Pathol"},{"key":"2021122508122609900_onco12140-bib-0009","doi-asserted-by":"crossref","first-page":"52584","DOI":"10.18632\/oncotarget.9683","article-title":"Genetic and molecular alterations in olfactory neuroblastoma: Implications for pathogenesis, prognosis and treatment","volume":"7","author":"Czapiewski","year":"2016","journal-title":"Oncotarget"},{"key":"2021122508122609900_onco12140-bib-0010","doi-asserted-by":"crossref","first-page":"e37029","DOI":"10.1371\/journal.pone.0037029","article-title":"Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma","volume":"7","author":"Weiss","year":"2012","journal-title":"PLoS One"},{"key":"2021122508122609900_onco12140-bib-0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-0034-1390011","article-title":"Esthesioneuroblastoma: An update on the UCLA experience, 2002-2013","volume":"76","author":"Tajudeen","year":"2015","journal-title":"J Neurol Surg B Skull Base"},{"key":"2021122508122609900_onco12140-bib-0012","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ctrv.2015.07.004","article-title":"The role of systemic therapy in the management of sinonasal cancer: A critical review","volume":"41","author":"Bossi","year":"2015","journal-title":"Cancer Treatment Rev"},{"key":"2021122508122609900_onco12140-bib-0013","doi-asserted-by":"crossref","first-page":"774","DOI":"10.12998\/wjcc.v3.i9.774","article-title":"Esthesioneuroblastoma: Multimodal management and review of literature","volume":"3","author":"Kumar","year":"2015","journal-title":"World J Clin Cases"},{"key":"2021122508122609900_onco12140-bib-0014","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11060-009-0027-x","article-title":"Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate","volume":"97","author":"Preusser","year":"2010","journal-title":"J Neurooncol"},{"key":"2021122508122609900_onco12140-bib-0015","doi-asserted-by":"crossref","first-page":"e3536","DOI":"10.1097\/MD.0000000000003536","article-title":"Recurrent olfactory neuroblastoma treated with cetuximab and sunitinib: A case report","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2021122508122609900_onco12140-bib-0016","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00280-011-1734-5","article-title":"A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors","volume":"69","author":"Fury","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122508122609900_onco12140-bib-0017","first-page":"e12513","article-title":"Imatinib mesylate as second-line treatment in a c-kit-positive esthesioneuroblastoma","volume":"29","author":"Kim","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"key":"2021122508122609900_onco12140-bib-0018","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4081\/rt.2012.e33","article-title":"Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab","volume":"4","author":"Dunbar","year":"2012","journal-title":"Rare Tumors"},{"key":"2021122508122609900_onco12140-bib-0019","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2021122508122609900_onco12140-bib-0020","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"key":"2021122508122609900_onco12140-bib-0021","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer","volume":"39","author":"Forbes","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2021122508122609900_onco12140-bib-0022","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MOO.0b013e3283506870","article-title":"Cytogenetic analysis of skull base tumors: Where do we stand?","volume":"20","author":"Gil","year":"2012","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"2021122508122609900_onco12140-bib-0023","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0165-4608(91)90198-4","article-title":"Trisomy 8 in primary esthesioneuroblastoma","volume":"57","author":"VanDevanter","year":"1991","journal-title":"Cancer Genet Cytogenet"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0287","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0287","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/7\/834\/41915986\/oncolo_22_7_834.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/7\/834\/41915986\/oncolo_22_7_834.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:12:54Z","timestamp":1640419974000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/7\/834\/6444383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,11]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,5,11]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0287","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7,1]]},"published":{"date-parts":[[2017,5,11]]}}}